<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509911</url>
  </required_header>
  <id_info>
    <org_study_id>TLH-206</org_study_id>
    <nct_id>NCT01509911</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tiltan Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technostat</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novatrials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tiltan Pharma Ltd.</source>
  <brief_summary>
    <textblock>
      TL-118 is an anti-angiogenic drug combination designed for the treatment of cancer. The&#xD;
      investigational product Tl-118 comprises of four well-known active components. The therapy is&#xD;
      administrated at a unique dosing regimen that was found to be effective and advantageous in&#xD;
      terms of safety. The product is formulated as an oral suspension, conveniently administrated&#xD;
      by the patients at home and not requiring medical staff assistance. This Phase II clinical&#xD;
      trial aims to evaluate the efficacy, safety and tolerability of TL-118 in Gemcitabine treated&#xD;
      Pancreatic Cancer patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate as defined by Percentage of patients experiencing a Complete Response or a Partial Response or a Stable Disease according to RECIST measured at 16 weeks after treatment initiation</measure>
    <time_frame>16 weeks after treatment initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Measured at week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline to study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Measured at week 16 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Measured at week 16 and 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>TL-118 with standard of care Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine with out TL-118</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TL-118</intervention_name>
    <description>TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.</description>
    <arm_group_label>TL-118 with standard of care Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Monthly cycles of 3 weekly treatments a month and one week off of treatment</description>
    <arm_group_label>Gemcitabine with out TL-118</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age at least 18 years at enrollment.&#xD;
&#xD;
          2. Metastatic Pancreatic Cancer&#xD;
&#xD;
          3. The patient has histologically or cytologically confirmed pancreatic adenocarcinoma.&#xD;
&#xD;
          4. Patient has measurable disease by (RECIST).&#xD;
&#xD;
          5. Patient is starting standard of care Gemcitabine treatment&#xD;
&#xD;
          6. ECOG performance status â‰¤ 1&#xD;
&#xD;
          7. Adequate renal function&#xD;
&#xD;
          8. Adequate hepatic function&#xD;
&#xD;
          9. Adequate bone marrow reserve&#xD;
&#xD;
         10. Resolution of prior therapy acute adverse events.&#xD;
&#xD;
         11. Patient is capable of swallowing.&#xD;
&#xD;
         12. Patient's Informed Consent. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to one or more of the TL-118 active components&#xD;
&#xD;
          2. Known Glucose-6-phosphate-dehydrogenase deficiency (G6PD).&#xD;
&#xD;
          3. CNS or Brain metastases&#xD;
&#xD;
          4. Prior systemic therapy for pancreas cancer&#xD;
&#xD;
          5. Subjects who received any investigational medication, prior local therapy for pancreas&#xD;
             cancer , or any significant change in treatment within 1 month prior to screening&#xD;
&#xD;
          6. Concurrent use of any other investigational product&#xD;
&#xD;
          7. Subjects with a clinically significant or unstable medical condition that would&#xD;
             preclude safe and complete study participation&#xD;
&#xD;
          8. Use of supplements or complementary medicines/botanicals, except for conventional&#xD;
             multivitamin supplements, calcium, selenium and soy supplements.&#xD;
&#xD;
          9. Patient has known historical or active infection with HIV, hepatitis B, or hepatitis C&#xD;
&#xD;
         10. Circumstances likely to interfere with absorption of orally administrated drugs.&#xD;
&#xD;
         11. History of noncompliance to medical regimens or coexisting -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>White Plains Hospital</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HaEmek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2012</study_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

